Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2003-01-21
2009-08-11
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S178000
Reexamination Certificate
active
07572780
ABSTRACT:
A method for reducing the symptoms of peripheral vascular disease wherein a chemical agent that reduces peripheral vascular hyperreactivity in response to a stimulus for contraction of peripheral vascular musculature is administered to a subject in need thereof. Kits for administering the chemical agent to reduce the symptoms of peripheral vascular disease.
REFERENCES:
patent: 4196188 (1980-04-01), Besins
patent: 4900734 (1990-02-01), Maxson et al.
patent: 5422119 (1995-06-01), Casper
patent: 5612051 (1997-03-01), Yue
patent: 5859001 (1999-01-01), Simpkins et al.
patent: 5891462 (1999-04-01), Carrara
patent: 5968918 (1999-10-01), Kanda
patent: 5985861 (1999-11-01), Levine et al.
patent: 5998638 (1999-12-01), Bender
patent: 6054447 (2000-04-01), Levine et al.
patent: 6056972 (2000-05-01), Hermsmeyer
patent: 6228852 (2001-05-01), Shaak
patent: 6440954 (2002-08-01), Haber et al.
patent: 2002/0156090 (2002-10-01), Day et al.
patent: 3514724 (1986-03-01), None
patent: 0 279 977 (1988-08-01), None
patent: 0 399 432 (1990-11-01), None
patent: 0754701 (1997-01-01), None
patent: WO 95/07699 (1995-03-01), None
patent: WO 96/09826 (1996-04-01), None
patent: 97/46242 (1997-12-01), None
patent: 98/50042 (1998-11-01), None
patent: 98/50415 (1998-11-01), None
patent: 01/47451 (2001-07-01), None
patent: 2004/019953 (2004-03-01), None
patent: 2004/024206 (2004-03-01), None
Sitruk-Ware et al. “Oral micronized progesterone, bioavailability pharmaceutics, pharmaological and therapeutic implications,—a review,” Contraception, 1987, vol. 36, No. 4, pp. 373-402.
Ahrensfield, DC, et al, “How to Diagnose and Manage Occlusive Peripheral Arterial Disease”, Women's Health in Primary Care, 1(6):500-507 (1998).
Mercuro, G, et al, “Effects of acute administration of natural progesterone on peripheral vascular responsiveness in healthy postmenopausal women”, American Journal of Cardiology, 84(2):214-218 (1999) (Abstract Only).
Myers, Si, et al “Estrogen increases male rat aortic endothelial cell (RAEC) PGI2 release”, Prostaglandins, 54(6):403-409 (1996).
White, MM, et al., “Estrogen, Progesterone, and Vascular Reactivity; Potential Cellular Mechanisms”, Endocrine Review, 16(6):739-751 (1995).
Rylance, PB, et al., “Natural Progesterone and antihypertensive action”, British Medical Journal, 290:13-14 (1985).
Miyagawa K., et al., “Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm”, Nature Medicine, 3(3):324-327 (1997).
Miyagawa K., et al., “Ca+2release mechanism of primate drug-induced coronary vasospasm”, American Journal of Physiology, 272:H2645-H2654 (1997).
Jiang, C, et al., “Progesterone Induces endothelium-independent relaxation of rabbit coronary artery in vitro” European Journal of Pharmacology, 211:163-167 (1992).
Karmazyn, M. et al., “The Mechanism of Coronary Artery Spasm: Roles of Oxygen, Prostaglandins, Sex Hormones and Smoking”, Medical Hypotheses, 5:447-452 (1979).
The Writing Group for the Pepi Trial, “Effects of Estrogen or Estrogen/Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women”, Journal of American Medical Association, 273(3):199-208 (1995).
Ford, SP, et al., “Role of Estradiol-17β and Progesterone in Regulating Constriction of Ovine Uterine Arteries”, Biology of Reproduction, 17:480-483 (1977).
Hiatt, WR, “Medical Treatment of Peripheral Arterial Disease and Claudication”, The New England J. of Med., 344:1608-1621 (2001).
Makin, AJ, et al., “ABC of Antithrombotic Therapy: Antithrombotic Therapy in Peripheral Vascular Disease”, BMJ, 325:1101-1104 (Nov. 2002).
Bosch, JL, et al., “Health-related Quality of Life After Angioplasty and Stent Placement in Patients with Iliac Artery Occlusive Disease”, Circulation, 99:3155-3160 (1999).
Moulds, RFW, et al., “The Effects of Platelet-Derived Contractile Agents on Human Digital Arteries”, Clinical Science, 66:443-451 (1984).
Barbagallo, M., et al, “Vascular Effects of Progesterone, Role of Cellular Calcium Regulation,” Hypertension, 37:142-147 (2001).
Barterlink, ML, et al, “The effects of single oral doses of 17B-estradiol and progesterone on finger skin circulation in healthy women and in women with primary Raynaud's phenomenon,” Eur. J. Clin. Pharmacol., 46:557-560 (1994).
Dawson, DL, et al, “Peripheral arterial disease: Medical care and prevention of complications,” Preventive Cardiology, 5:119-130 (2002).
Fraenkel, L, et al, “The association of estrogen replacement therapy and Raynaud's phenomenon in postmenopausal women,” Annals Internal Medicine, 129(3):208-211 (1998).
Korting, GW, et al, “Gestagen-Behandlung der Sklerodermie,” Aesth. Med., 16(10):291-294 (1967).
Pai, MP, et al, “Treatment of thrombo-angitis obliterans—a study of 74 cases,” Antiseptic, 66(7):495-502 (1969).
Rosano, GMC, et al, “Comparative Cardiovascular Effects of Different Progestins in Menopause,” Int. J. Fertil., 46 (5):248-256 (2001).
Dimera Incorporated
Eisenberg, Esq. Howard
Wang Shengjun
LandOfFree
Method and kit for reducing the symptoms of peripheral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and kit for reducing the symptoms of peripheral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and kit for reducing the symptoms of peripheral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4138056